We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
News

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
News

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Arrowhead Research Corporation has announced that majority-owned subsidiary Calando Pharmaceuticals has published results in the Proceedings of the National Academy of Sciences (PNAS) of the first non-human primate study to use multiple, systemic dosing with Calando's lead siRNA therapeutic candidate.

Calando is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to create targeted siRNA therapeutics. Its lead anti-cancer therapeutic candidate contains a linear cyclodextrin polymer, the siRNA, and a targeting agent. The formulation self assembles into nanoparticles that protect the siRNA from nuclease degradation in serum.

The Company says that one important result of the study was the lack of a significant immune response to the siRNA, demonstrating that the formulation is well tolerated at doses much higher than those previously shown to have anti-cancer effects.

Advertisement